BBIO
HOLD / NEUTRALMeanRevComposite
52.80
Technical
35.60
Fundamental
58.50
Rank
—
Price
70.73
Hurst
0.06
As of
Oct 30, 2026
Daily
BridgeBio Pharma Inc
HEALTHCAREBIOTECHNOLOGYBridgeBio Pharma is a pharmaceutical firm focused on identifying and bringing to market treatments for inherited genetic conditions. Based in Palo Alto, California, the company operates across drug discovery, development, and manufacturing activities.
Market cap
$14.7B
P/E (trailing)
—
P/E (forward)
—
PEG ratio
—
Dividend yield
—
Beta
0.97
52w range
60.22 – 93.42
Return on equity
-1790.00%
Profit margin
-97.00%
Revenue growth
+120.40%
Earnings growth
0.00%
Price history
1Y: 74.95 (+19.6%) · range 61.37–90.17
Cycle position
47/ 100 cycle scoreMID-BULL
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 33 · NOT READY · exit proximity 0
Conviction
39/ 100 · maturity 14%
VScore.0919
Buildup.3039
EMA entry setup.3833
Fundamentals.2359
Volume profile
POC
67.14
Price vs POC
+5.3%
Overhead supply
45%
Runway
open sky
Value area 63.12–77.96 · 45% of 120d volume overhead · moderate overhead
Contributing sources
| Source | Score | Last seen |
|---|---|---|
| earnings-surprise | 0.967 | Oct 30, 2026 |
Pattern & cluster
Pattern
NEUTRAL
Cluster
NEUTRALForward returns
Not yet labeled — the study prices these as positions mature.